ranosidenib
ranosidenib: 3 clinical trials tracked.
ranosidenib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about ranosidenib, and what remains unknown?
Traceable citations · Unknowns marked
Clinical Trial Registry Records (3)
A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations
Primary endpoint: Number of Subjects with Dose Limiting Toxicities (DLTs)
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
Primary endpoint: Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations
Primary endpoint: Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306